

Franziska Michor

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9580632/franziska-michor-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137
papers

10,565
citations

53
h-index

102
g-index

144
ext. papers

12,884
ext. citations

13
avg, IF

6.32
L-index

#	Paper	IF	Citations
137	Designing optimal allocations for cancer screening using queuing network models. <i>PLoS Computational Biology</i> , 2022 , 18, e1010179	5	
136	Response to comment on "Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2". <i>Science Translational Medicine</i> , 2021 , 13, eabj3222	17.5	3
135	Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. <i>Cell Stem Cell</i> , 2021 , 28, 514-523.e9	18	42
134	Breast tumours maintain a reservoir of subclonal diversity during expansion. <i>Nature</i> , 2021 , 592, 302-308	50.4	33
133	A Quantitative Paradigm for Decision-Making in Precision Oncology. <i>Trends in Cancer</i> , 2021 , 7, 293-300	12.5	2
132	Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma. <i>Nature Biomedical Engineering</i> , 2021 , 5, 346-359	19	4
131	The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer. <i>JCI Insight</i> , 2021 , 6,	9.9	3
130	Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer. <i>Nature Communications</i> , 2021 , 12, 3697	17.4	5
129	Progression signature underlies clonal evolution and dissemination of multiple myeloma. <i>Blood</i> , 2021 , 137, 2360-2372	2.2	9
128	Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML. <i>Nature Communications</i> , 2021 , 12, 245	17.4	5
127	Topological isolation of developmental regulators in mammalian genomes. <i>Nature Communications</i> , 2021 , 12, 4897	17.4	2
126	Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses. <i>Npj Precision Oncology</i> , 2021 , 5, 85	9.8	1
125	Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. <i>Nature Communications</i> , 2020 , 11, 2350	17.4	15
124	Pharmacokinetic Profiles Determine Optimal Combination Treatment Schedules in Computational Models of Drug Resistance. <i>Cancer Research</i> , 2020 , 80, 3372-3382	10.1	4
123	Ascl2-Dependent Cell Dedifferentiation Drives Regeneration of Ablated Intestinal Stem Cells. <i>Cell Stem Cell</i> , 2020 , 26, 377-390.e6	18	77
122	Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2-Mutant Myeloproliferative Neoplasms. <i>Blood</i> , 2020 , 136, 7-8	2.2	4
121	Drug Sensitivity and Allele-specificity of First-line Osimertinib Resistance EGFR Mutations. <i>FASEB Journal</i> , 2020 , 34, 1-1	0.9	

120	Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. <i>Molecular Cell</i> , 2020 , 78, 1096-1113.e8	17.6	35
119	Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	110
118	Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms. <i>Haematologica</i> , 2020 , 105, e91-e94	6.6	
117	Circadian clock effects on cellular proliferation: Insights from theory and experiments. <i>Current Opinion in Cell Biology</i> , 2020 , 67, 17-26	9	7
116	Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance Mutations. <i>Cancer Research</i> , 2020 , 80, 2017-2030	10.1	27
115	Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. <i>PLoS ONE</i> , 2019 , 14, e0215409 ^{3.7}	3.7	4
114	DIFFpop: a stochastic computational approach to simulate differentiation hierarchies with single cell barcoding. <i>Bioinformatics</i> , 2019 , 35, 3849-3851	7.2	1
113	Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments. <i>Nature Cell Biology</i> , 2019 , 21, 879-888	23.4	69
112	Increased expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma. <i>Genes and Development</i> , 2018 , 32, 512-523	12.6	21
111	Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2018 , 4, 10	7.8	58
110	A PDGFRE-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine. <i>Nature Communications</i> , 2018 , 9, 3116	17.4	17
109	Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. <i>PLoS Computational Biology</i> , 2018 , 14, e1005924	5	21
108	Deciphering Clonal Evolution and Dissemination of Multiple Myeloma Cells In Vivo. <i>Blood</i> , 2018 , 132, 55-55	2.2	
107	Computational Model of Progression to Multiple Myeloma Identifies Optimum Screening Strategies. <i>JCO Clinical Cancer Informatics</i> , 2018 , 2, 1-12	5.2	8
106	KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. <i>Cancer Cell</i> , 2018 , 34, 939-953.e9	24.3	93
105	Hidden heterogeneity and circadian-controlled cell fate inferred from single cell lineages. <i>Nature Communications</i> , 2018 , 9, 5372	17.4	22
104	Fitness variation in isogenic populations leads to a novel evolutionary mechanism for crossing fitness valleys. <i>Communications Biology</i> , 2018 , 1, 151	6.7	2
103	Currently available bulk sequencing data do not necessarily support a model of neutral tumor evolution. <i>Nature Genetics</i> , 2018 , 50, 1620-1623	36.3	17

102	Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq. <i>Nature Communications</i> , 2018 , 9, 3588	17.4	187
101	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1598-1605	2.2	208
100	Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution. <i>Cancer Research</i> , 2017 , 77, 3908-3921	10.1	36
99	Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells. <i>Nucleic Acids Research</i> , 2017 , 45, e77	20.1	24
98	The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. <i>Cell Reports</i> , 2017 , 19, 218-224	6.6	67
97	SIApopr: a computational method to simulate evolutionary branching trees for analysis of tumor clonal evolution. <i>Bioinformatics</i> , 2017 , 33, 2221-2223	7.2	5
96	Mathematical Modeling Links Pregnancy-Associated Changes and Breast Cancer Risk. <i>Cancer Research</i> , 2017 , 77, 2800-2809	10.1	5
95	mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors. <i>Cancer Discovery</i> , 2017 , 7, 1450-1463	24.4	59
94	Nuclear topology modulates the mutational landscapes of cancer genomes. <i>Nature Structural and Molecular Biology</i> , 2017 , 24, 1000-1006	17.6	22
93	Distance in cancer gene expression from stem cells predicts patient survival. <i>PLoS ONE</i> , 2017 , 12, e0173589	3.7	7
92	Estimating mono- and bi-phasic regression parameters using a mixture piecewise linear Bayesian hierarchical model. <i>PLoS ONE</i> , 2017 , 12, e0180756	3.7	1
91	Analysis of somatic microsatellite indels identifies driver events in human tumors. <i>Nature Biotechnology</i> , 2017 , 35, 951-959	44.5	72
90	Immune Escape in Breast Cancer During to Invasive Carcinoma Transition. <i>Cancer Discovery</i> , 2017 , 7, 1098-1115	11.13	113
89	A computational strategy to adjust for copy number in tumor Hi-C data. <i>Bioinformatics</i> , 2016 , 32, 3695-3701	3.7	31
88	Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. <i>Nature Genetics</i> , 2016 , 48, 1119-30	36.3	290
87	ABCG2 regulates self-renewal and stem cell marker expression but not tumorigenicity or radiation resistance of glioma cells. <i>Scientific Reports</i> , 2016 , 6, 25956	4.9	36
86	Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. <i>Clinical Cancer Research</i> , 2016 , 22, 4206-4214	12.9	18
85	Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Blood</i> , 2016 , 128, 986-986	2.2	1

84	In Vivo Analysis of Clonal Evolution of Multiple Myeloma. <i>Blood</i> , 2016 , 128, 799-799	2.2	
83	Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease. <i>American Journal of Hematology</i> , 2016 , 91, 931-7	7.1	22
82	Probabilistic Modeling of Reprogramming to Induced Pluripotent Stem Cells. <i>Cell Reports</i> , 2016 , 17, 3395-3406	10.10	
81	DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. <i>BMC Cancer</i> , 2015 , 15, 242	4.8	20
80	Polyploidy can drive rapid adaptation in yeast. <i>Nature</i> , 2015 , 519, 349-52	50.4	258
79	Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. <i>Nature Medicine</i> , 2015 , 21, 440-8	50.5	273
78	Stochastic tunneling and metastable states during the somatic evolution of cancer. <i>Genetics</i> , 2015 , 199, 1213-28	4	9
77	In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. <i>Nature Genetics</i> , 2015 , 47, 1212-9	36.3	117
76	The mathematics of cancer: integrating quantitative models. <i>Nature Reviews Cancer</i> , 2015 , 15, 730-45	31.3	357
75	Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort. <i>Cell</i> , 2015 , 163, 1059-1063	56.2	71
74	The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. <i>Cancer Informatics</i> , 2015 , 14, 19-31	2.4	48
73	An Evolutionary Approach for Identifying Driver Mutations in Colorectal Cancer. <i>PLoS Computational Biology</i> , 2015 , 11, e1004350	5	21
72	CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. <i>Cell Reports</i> , 2015 , 12, 622-35	10.6	94
71	JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. <i>Cancer Discovery</i> , 2015 , 5, 316-31	24.4	188
70	Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma. <i>Blood</i> , 2015 , 126, 23-23	2.2	10
69	Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients. <i>PLoS ONE</i> , 2015 , 10, e0141665	3.7	15
68	Understanding tissue context influences on intratumour heterogeneity. <i>Nature Cell Biology</i> , 2014 , 16, 301-2	23.4	20
67	Genetic and phenotypic diversity in breast tumor metastases. <i>Cancer Research</i> , 2014 , 74, 1338-48	10.1	137

66	Epigenetic diversity in hematopoietic neoplasms. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1846, 477-84	11.2	10
65	Clonal evolution in breast cancer revealed by single nucleus genome sequencing. <i>Nature</i> , 2014 , 512, 155-60	50.4	730
64	Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. <i>Cancer Cell</i> , 2014 , 26, 288-300	24.3	261
63	Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. <i>Nature</i> , 2014 , 514, 54-8	50.4	397
62	Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. <i>Cell</i> , 2014 , 156, 603-616	56.2	184
61	Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. <i>Haematologica</i> , 2014 , 99, 1701-9	6.6	12
60	On the validity of using increases in 5-year survival rates to measure success in the fight against cancer. <i>PLoS ONE</i> , 2014 , 9, e83100	3.7	18
59	Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. <i>Clinical Cancer Research</i> , 2014 , 20, 1873-83	12.9	38
58	Histone modifications are associated with transcript isoform diversity in normal and cancer cells. <i>PLoS Computational Biology</i> , 2014 , 10, e1003611	5	18
57	Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. <i>Cell Reports</i> , 2014 , 6, 514-27	10.6	194
56	Evolution of acquired resistance to anti-cancer therapy. <i>Journal of Theoretical Biology</i> , 2014 , 355, 10-20	2.3	167
55	Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	123
54	Meta-analysis of public microarray databases for prognostic and predictive gene signatures of late-stage ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5531-5531	2.2	
53	DNA replication timing and higher-order nuclear organization determine single-nucleotide substitution patterns in cancer genomes. <i>Nature Communications</i> , 2013 , 4, 1502	17.4	82
52	Patterns of proliferative activity in the colonic crypt determine crypt stability and rates of somatic evolution. <i>PLoS Computational Biology</i> , 2013 , 9, e1003082	5	19
51	Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. <i>PLoS Genetics</i> , 2013 , 9, e1003137	6	91
50	Stochastic Tunneling of Two Mutations in a Population of Cancer Cells. <i>PLoS ONE</i> , 2013 , 8, e65724	3.7	7
49	Genomic characterization of metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 247-247		

48	Peroxisome proliferator-activated receptor gamma (PPARG) gene amplifications in urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 279-279	2.2	
47	Epigenetic Deregulation In Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2013 , 122, 2499-2499	2.2	1
46	Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1583-93	8.9	58
45	Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. <i>Cell</i> , 2012 , 148, 362-75	56.2	292
44	A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. <i>PLoS Computational Biology</i> , 2012 , 8, e1002337	5	46
43	A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability. <i>PLoS Computational Biology</i> , 2012 , 8, e1002370	5	9
42	Analyzing the association of SCNA boundaries with replication timing. <i>Nature Biotechnology</i> , 2012 , 30, 1045-1046	44.5	
41	FGFR3 protein expression and gene mutation in primary and metastatic urothelial carcinoma (UC) tumors.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4577-4577	2.2	1
40	External validation of somatic copy number alteration (SCNA) at chromosome 1q23.3 in advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4585-4585	2.2	
39	DNA secondary structures and epigenetic determinants of cancer genome evolution. <i>Nature Structural and Molecular Biology</i> , 2011 , 18, 950-5	17.6	169
38	Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. <i>Science Translational Medicine</i> , 2011 , 3, 90ra59	17.5	383
37	Intratumor heterogeneity in evolutionary models of tumor progression. <i>Genetics</i> , 2011 , 188, 461-77	4	86
36	DNA replication timing and long-range DNA interactions predict mutational landscapes of cancer genomes. <i>Nature Biotechnology</i> , 2011 , 29, 1103-8	44.5	129
35	Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. <i>Blood</i> , 2011 , 118, 1622-31	2.2	52
34	What does physics have to do with cancer?. <i>Nature Reviews Cancer</i> , 2011 , 11, 657-70	31.3	143
33	DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. <i>Blood</i> , 2011 , 118, 3559-69	2.2	107
32	Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. <i>Molecular Pharmaceutics</i> , 2011 , 8, 2069-79	5.6	40
31	Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. <i>PLoS ONE</i> , 2011 , 6, e27682	3.7	44

30	Reply to Parsons: Many tumor types follow the monoclonal model of tumor initiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, E16-E16	11.5	4
29	Evolutionary dynamics of intratumor heterogeneity. <i>PLoS ONE</i> , 2011 , 6, e17866	3.7	44
28	The probable cell of origin of NF1- and PDGF-driven glioblastomas. <i>PLoS ONE</i> , 2011 , 6, e24454	3.7	26
27	Epigenetic Profiling of Primary DLBCLs Reveals Novel DNA Methylation-Based Clusters and New Underlying Mechanisms of Lymphomagenesis. <i>Blood</i> , 2011 , 118, 556-556	2.2	
26	Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. <i>Journal of Clinical Investigation</i> , 2010 , 120, 636-44	15.9	258
25	The origins and implications of intratumor heterogeneity. <i>Cancer Prevention Research</i> , 2010 , 3, 1361-4	3.2	141
24	A differentiation-based phylogeny of cancer subtypes. <i>PLoS Computational Biology</i> , 2010 , 6, e1000777	5	30
23	A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 17604-9	11.5	99
22	Evolution of resistance to anti-cancer therapy during general dosing schedules. <i>Journal of Theoretical Biology</i> , 2010 , 263, 179-88	2.3	62
21	The therapeutic implications of plasticity of the cancer stem cell phenotype. <i>PLoS ONE</i> , 2010 , 5, e14366	3.7	43
20	Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. <i>PLoS Computational Biology</i> , 2009 , 5, e1000557	5	85
19	The evolution of two mutations during clonal expansion. <i>Genetics</i> , 2007 , 177, 2209-21	4	47
18	Evolution of resistance to cancer therapy. <i>Current Pharmaceutical Design</i> , 2006 , 12, 261-71	3.3	68
17	Evolution of resistance during clonal expansion. <i>Genetics</i> , 2006 , 172, 2557-66	4	168
16	The age incidence of chronic myeloid leukemia can be explained by a one-mutation model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 14931-4	11.5	65
15	Stochastic dynamics of metastasis formation. <i>Journal of Theoretical Biology</i> , 2006 , 240, 521-30	2.3	52
14	Dynamics of chronic myeloid leukaemia. <i>Nature</i> , 2005 , 435, 1267-70	50.4	667
13	Can chromosomal instability initiate tumorigenesis?. <i>Seminars in Cancer Biology</i> , 2005 , 15, 43-9	12.7	150

12	Dynamics of colorectal cancer. <i>Seminars in Cancer Biology</i> , 2005 , 15, 484-93	12.7	93
11	Chromosomal instability and human cancer. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2005 , 360, 631-5	5.8	18
10	Stochastic tunnels in evolutionary dynamics. <i>Genetics</i> , 2004 , 166, 1571-9	4	176
9	Evolutionary dynamics of tumor suppressor gene inactivation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 10635-8	11.5	81
8	Dynamics of cancer progression. <i>Nature Reviews Cancer</i> , 2004 , 4, 197-205	31.3	311
7	Linear model of colon cancer initiation. <i>Cell Cycle</i> , 2004 , 3, 358-62	4.7	36
6	Stochastic elimination of cancer cells. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2003 , 270, 2017-24	4.4	38
5	The linear process of somatic evolution. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 14966-9	11.5	149
4	Local regulation of homeostasis favors chromosomal instability. <i>Current Biology</i> , 2003 , 13, 581-4	6.3	34
3	Somatic selection for and against cancer. <i>Journal of Theoretical Biology</i> , 2003 , 225, 377-82	2.3	48
2	Evolutionary dynamics of escape from biomedical intervention. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2003 , 270, 2573-8	4.4	69
1	Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in JAK2-mutant myeloproliferative neoplasms		1